Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
30.87
-0.18 (-0.58%)
At close: Dec 5, 2025, 4:00 PM EST
31.04
+0.17 (0.55%)
After-hours: Dec 5, 2025, 5:13 PM EST
Stoke Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Stoke Therapeutics stock have an average target of 31, with a low estimate of 24 and a high estimate of 39. The average target predicts an increase of 0.42% from the current stock price of 30.87.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 5, 2025.
Analyst Ratings
The average analyst rating for Stoke Therapeutics stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 5 | 6 | 6 |
| Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 7 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $24 → $28 | Strong Buy | Maintains | $24 → $28 | -9.30% | Nov 5, 2025 |
| Wedbush | Wedbush | Buy Maintains $22 → $32 | Buy | Maintains | $22 → $32 | +3.66% | Nov 5, 2025 |
| BTIG | BTIG | Strong Buy Reiterates $39 | Strong Buy | Reiterates | $39 | +26.34% | Nov 5, 2025 |
| JP Morgan | JP Morgan | Hold Maintains $15 → $25 | Hold | Maintains | $15 → $25 | -19.02% | Nov 3, 2025 |
| BTIG | BTIG | Strong Buy Maintains $28 → $39 | Strong Buy | Maintains | $28 → $39 | +26.34% | Oct 13, 2025 |
Financial Forecast
Revenue This Year
193.83M
from 36.56M
Increased by 430.24%
Revenue Next Year
34.88M
from 193.83M
Decreased by -82.00%
EPS This Year
0.16
from -1.65
EPS Next Year
-3.17
from 0.16
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 209.7M | 73.5M | ||||
| Avg | 193.8M | 34.9M | ||||
| Low | 182.3M | 11.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 473.6% | -62.1% | ||||
| Avg | 430.2% | -82.0% | ||||
| Low | 398.7% | -93.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 0.45 | -2.61 | ||||
| Avg | 0.16 | -3.17 | ||||
| Low | 0.02 | -3.58 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.